The Experts below are selected from a list of 3714 Experts worldwide ranked by ideXlab platform
William C Stewart - One of the best experts on this subject based on the ideXlab platform.
-
24 hour intraocular pressures with Brimonidine purite versus dorzolamide added to latanoprost in primary open angle glaucoma subjects
Ophthalmology, 2005Co-Authors: Anastasios G P Konstas, Costas H Karabatsas, Nikolaos Lallos, Nikolaos Georgiadis, Aikaterini Kotsimpou, Jeanette A Stewart, William C StewartAbstract:OBJECTIVE: To evaluate the 24-hour efficacy of Brimonidine purite versus dorzolamide, each added to latanoprost. DESIGN: Double-masked, 2-center, prospective, crossover comparison. PARTICIPANTS: Primary open-angle glaucoma (POAG) subjects. METHODS: Subjects were randomized to Brimonidine purite or dorzolamide, each given twice daily, for the first 6-week treatment period after a 6-week latanoprost run-in. Subjects began the opposite treatment for the second 6-week period after a 6-week latanoprost-only treatment between periods. Intraocular pressure (IOP) was measured at 8 am, 12 pm, 4 pm, 8 pm, 12 am, 4 am, and 8 am at each baseline and at the end of each treatment period. This study provided an 80% power that a 1.5-mmHg difference could be excluded between groups if 27 subjects completed the study. A standard deviation (SD) of 2.8 mmHg was assumed. MAIN OUTCOME MEASURES: Twenty-four-hour efficacy of intraocular pressures of Brimonidine purite versus dorzolamide, each added to latanoprost. RESULTS: In 31 completed subjects, the baseline mean diurnal 24-hour IOP (+/- SD) was 19.0+/-1.7 mmHg for Brimonidine purite and 19.0+/-1.6 mmHg for dorzolamide (P = 0.52). The 8 am IOP after 6 weeks of therapy was 18.4+/-2.1 mmHg for Brimonidine purite and 18.9+/-1.9 mmHg for dorzolamide (P = 0.40). The mean diurnal IOP was 16.9+/-1.5 mmHg for Brimonidine purite and 16.8+/-1.5 mmHg for dorzolamide (P = 0.66). Dorzolamide caused a more bitter taste (P = 0.01) than Brimonidine purite. CONCLUSIONS: This study suggests that Brimonidine purite and dorzolamide, added to latanoprost, have similar efficacy and safety in POAG or ocular hypertensive subjects.
-
Cardiovascular effects of timolol maleate, Brimonidine or Brimonidine/timolol maleate in concomitant therapy
Acta ophthalmologica Scandinavica, 2002Co-Authors: William C Stewart, Jeanette A Stewart, Angi L. JacksonAbstract:. Purpose: To examine the influence on maximal exercise performance in young healthy volunteers of timolol 0.5%, Brimonidine 0.2% or placebo versus Brimonidine 0.2% and timolol 0.5% used concomitantly. Methods: The subjects in this prospective, double-masked, crossover comparison were dosed 15 min prior to treadmill testing. A period of 1 week was allowed between tests. Results: The 20 subjects who completed the trials (average age 24.5 ± 7.4) had a mean maximum exercise heart rate of 196 ± 12 bpm for placebo, 182 ± 13 bpm for timolol, 187 ± 10 bpm for Brimonidine, and 186 ± 11 bpm for timolol/Brimonidine concomitant therapy (p
-
washout periods for Brimonidine 0 2 and latanoprost 0 005
American Journal of Ophthalmology, 2001Co-Authors: William C Stewart, Keri T Holmes, Mark A JohnsonAbstract:PURPOSE: To evaluate the intraocular pressure washout time after discontinuing Brimonidine 0.2% twice daily and latanoprost 0.005% once every evening. METHODS: We discontinued Brimonidine or latanoprost in a masked fashion from primary open-angle glaucoma or ocular hypertensive patients. The intraocular pressure was measured twice weekly until patients returned to untreated baseline. RESULTS: In 32 patients, the mean longest eye washout time for Brimonidine (n = 15) was 3.3 ± 3.0 weeks and for latanoprost (n = 17) was 4.4 ± 3.2 weeks (P = .24). In all but one patient, Brimonidine returned to baseline by 5 weeks and latanoprost returned by 8 weeks. CONCLUSION: After discontinuing latanoprost or Brimonidine, a wide variation exists in washout times among individuals, with latanoprost demonstrating a trend to a longer washout period.
-
Washout periods for Brimonidine 0.2% and latanoprost 0.005%.
American Journal of Ophthalmology, 2001Co-Authors: William C Stewart, Keri T Holmes, Mark A JohnsonAbstract:PURPOSE: To evaluate the intraocular pressure washout time after discontinuing Brimonidine 0.2% twice daily and latanoprost 0.005% once every evening. METHODS: We discontinued Brimonidine or latanoprost in a masked fashion from primary open-angle glaucoma or ocular hypertensive patients. The intraocular pressure was measured twice weekly until patients returned to untreated baseline. RESULTS: In 32 patients, the mean longest eye washout time for Brimonidine (n = 15) was 3.3 ± 3.0 weeks and for latanoprost (n = 17) was 4.4 ± 3.2 weeks (P = .24). In all but one patient, Brimonidine returned to baseline by 5 weeks and latanoprost returned by 8 weeks. CONCLUSION: After discontinuing latanoprost or Brimonidine, a wide variation exists in washout times among individuals, with latanoprost demonstrating a trend to a longer washout period.
Amy L Batoosingh - One of the best experts on this subject based on the ideXlab platform.
-
Safety and tolerability of Brimonidine purite 0.1% and Brimonidine purite 0.15%: a meta-analysis of two phase 3 studies
Current medical research and opinion, 2009Co-Authors: Louis B. Cantor, Amy L Batoosingh, Ching Chi Liu, David A HollanderAbstract:ABSTRACTObjective: To compare the safety and tolerability of two formulations of Brimonidine ophthalmic solution, Brimonidine Purite (P) 0.1% and Brimonidine P 0.15%, for reducing intraocular pressure in patients with glaucoma or ocular hypertension (OHT). * Purite is a registered trademark of Allergan, Inc., Irvine, CA, USAStudy design and methods: Meta-analysis of safety and tolerability results from two previously reported prospective, randomized, 12-month, double-masked, multicenter, parallel-group clinical studies with similar entry criteria and protocols. In study 1 (two clinical trials), after washout of previous medications, patients with glaucoma or OHT were randomized to thrice-daily treatment with Brimonidine P 0.15% (n = 381), Brimonidine P 0.2% (n = 383), or Brimonidine 0.2% (n = 383). In study 2 (one clinical trial), the treatment arms were thrice-daily Brimonidine P 0.1% (n = 215) and Brimonidine 0.2% (n = 218).Main outcome measure: Treatment-related adverse events (AEs) and discontinuation...
-
Brimonidine-purite 0.1% versus Brimonidine-purite 0.15% twice daily in glaucoma or ocular hypertension : a 12-month randomized trial
Current medical research and opinion, 2008Co-Authors: Louis B. Cantor, Ching Chi Liu, Eleonora Safyan, Amy L BatoosinghAbstract:ABSTRACTObjective: To compare the safety and intraocular pressure (IOP)-lowering effects of Brimonidine-purite 0.1% with the marketed formulation of Brimonidine-purite 0.15% (Alphagan P 0.15%) when used twice daily (BID) by patients with glaucoma or ocular hypertension previously treated with Brimonidine-purite 0.15% for at least 6 weeks.Methods: In a 12-month, randomized, double-masked, multicenter, parallel group, non-inferiority study, patients with glaucoma or ocular hypertension who were treated with Brimonidine-purite 0.15% BID were randomly assigned to continue Brimonidine-purite 0.15% (n = 102) or to administer Brimonidine-purite 0.1% (n = 105) BID for 12 months. IOP was measured at approximately 8 a.m. (hour 0) and 10 a.m. (hour 2).Main outcome measures: Mean change from baseline IOP and adverse events.Results: Demographics and baseline characteristics were similar between treatment groups. Treated-baseline mean IOPs at both timepoints were similar between groups (p ≥ 0.606). Brimonidine-purite 0...
-
twice daily 0 2 Brimonidine 0 5 timolol fixed combination therapy vs monotherapy with timolol or Brimonidine in patients with glaucoma or ocular hypertension a 12 month randomized trial
Archives of Ophthalmology, 2006Co-Authors: Mark B Sherwood, Harvey Dubiner, Rhett M Schiffman, Randy E Craven, Connie Chou, Amy L Batoosingh, Scott M WhitcupAbstract:Objective To evaluate the intraocular pressure (IOP)–lowering efficacy and safety of a fixed combination of 0.2% Brimonidine tartrate and 0.5% timolol maleate (fixed Brimonidine-timolol) compared with the component medications. Methods In 2 identical, 12-month, randomized, double-masked multicenter trials, patients with ocular hypertension or glaucoma were treated with fixed Brimonidine-timolol twice daily (n = 385), 0.2% Brimonidine tartrate 3 times daily (n = 382), or 0.5% timolol maleate twice daily (n = 392). Main Outcomes Measures Mean change from baseline IOP and incidence of adverse events. Results The mean decrease from baseline IOP during 12-month follow-up was 4.4 to 7.6 mm Hg with fixed Brimonidine-timolol, 2.7 to 5.5 mm Hg with Brimonidine, and 3.9 to 6.2 mm Hg with timolol. Mean IOP reductions were significantly greater with fixed Brimonidine-timolol compared with timolol at all measurements (P≤.002) and Brimonidine at 8AM, 10AM, and 3PM(P Conclusions Twice-daily fixed Brimonidine-timolol therapy provides sustained IOP lowering superior to monotherapy with either thrice-daily Brimonidine or twice-daily timolol and is better tolerated than Brimonidine but less well tolerated than timolol. Application to Clinical Practice Fixed Brimonidine-timolol is an effective and convenient IOP-lowering therapy.
-
A 3-month comparison of efficacy and safety of Brimonidine-purite 0.15% and Brimonidine 0.2% in patients with glaucoma or ocular hypertension.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2003Co-Authors: Tom Mundorf, Scott M Whitcup, Robert Williams, Carlos Felix, Amy L BatoosinghAbstract:Purpose: To compare the efficacy and safety of Brimonidine Purite 0.15% (ALPHAGAN® P) BID with Brimonidine 0.2% (ALPHAGAN®) BID in patients with glaucoma or ocular hypertension. Methods: 3-month, multicenter, randomized, double-masked trial. Eligible patients were taking Brimonidine 0.2% BID for at least 6 weeks prior to study entry and their intraocular pressure (IOP) was ≤ 21 mm Hg. Patients were randomly assigned to receive either Brimonidine Purite 0.15% BID (n = 203) or Brimonidine 0.2% BID (n = 204). Scheduled visits were prestudy, baseline, and weeks 2, 6 and 12. IOP was measured at hour 0 and hour 2 to evaluate efficacy. Safety was measured by monitoring adverse events. Patient satisfaction and comfort were also evaluated at all visits. Results: There was no statistically significant difference between the Brimonidine 0.2% and Brimonidine Purite 0.15% groups with respect to mean IOP at baseline. The IOP-lowering efficacy of Brimonidine Purite 0.15% was equivalent to that of Brimonidine 0.2% and bo...
Louis B. Cantor - One of the best experts on this subject based on the ideXlab platform.
-
Safety and tolerability of Brimonidine purite 0.1% and Brimonidine purite 0.15%: a meta-analysis of two phase 3 studies
Current medical research and opinion, 2009Co-Authors: Louis B. Cantor, Amy L Batoosingh, Ching Chi Liu, David A HollanderAbstract:ABSTRACTObjective: To compare the safety and tolerability of two formulations of Brimonidine ophthalmic solution, Brimonidine Purite (P) 0.1% and Brimonidine P 0.15%, for reducing intraocular pressure in patients with glaucoma or ocular hypertension (OHT). * Purite is a registered trademark of Allergan, Inc., Irvine, CA, USAStudy design and methods: Meta-analysis of safety and tolerability results from two previously reported prospective, randomized, 12-month, double-masked, multicenter, parallel-group clinical studies with similar entry criteria and protocols. In study 1 (two clinical trials), after washout of previous medications, patients with glaucoma or OHT were randomized to thrice-daily treatment with Brimonidine P 0.15% (n = 381), Brimonidine P 0.2% (n = 383), or Brimonidine 0.2% (n = 383). In study 2 (one clinical trial), the treatment arms were thrice-daily Brimonidine P 0.1% (n = 215) and Brimonidine 0.2% (n = 218).Main outcome measure: Treatment-related adverse events (AEs) and discontinuation...
-
Brimonidine-purite 0.1% versus Brimonidine-purite 0.15% twice daily in glaucoma or ocular hypertension : a 12-month randomized trial
Current medical research and opinion, 2008Co-Authors: Louis B. Cantor, Ching Chi Liu, Eleonora Safyan, Amy L BatoosinghAbstract:ABSTRACTObjective: To compare the safety and intraocular pressure (IOP)-lowering effects of Brimonidine-purite 0.1% with the marketed formulation of Brimonidine-purite 0.15% (Alphagan P 0.15%) when used twice daily (BID) by patients with glaucoma or ocular hypertension previously treated with Brimonidine-purite 0.15% for at least 6 weeks.Methods: In a 12-month, randomized, double-masked, multicenter, parallel group, non-inferiority study, patients with glaucoma or ocular hypertension who were treated with Brimonidine-purite 0.15% BID were randomly assigned to continue Brimonidine-purite 0.15% (n = 102) or to administer Brimonidine-purite 0.1% (n = 105) BID for 12 months. IOP was measured at approximately 8 a.m. (hour 0) and 10 a.m. (hour 2).Main outcome measures: Mean change from baseline IOP and adverse events.Results: Demographics and baseline characteristics were similar between treatment groups. Treated-baseline mean IOPs at both timepoints were similar between groups (p ≥ 0.606). Brimonidine-purite 0...
-
Brimonidine in the treatment of glaucoma and ocular hypertension.
Therapeutics and clinical risk management, 2006Co-Authors: Louis B. CantorAbstract:Treatment in glaucoma aims to lower intraocular pressure (IOP) to reduce the risk of progression and vision loss. The alpha2-adrenergic receptor agonist Brimonidine effectively lowers IOP and is useful as monotherapy, adjunctive therapy, and replacement therapy in open-angle glaucoma and ocular hypertension. A fixed combination of Brimonidine and timolol, available in some countries, reduces IOP as effectively as concomitant therapy with Brimonidine and timolol and offers the convenience of 2 drugs in a single eyedrop. Brimonidine is safe and well tolerated. Its most common side-effects are conjunctival hyperemia, allergic conjunctivitis, and ocular pruritus. The newest formulation of Brimonidine, Brimonidine-Purite 0.1%, has a higher pH to improve the ocular bioavailability of Brimonidine. This formulation contains the lowest effective concentration of Brimonidine and is preserved with Purite® to enhance ocular tolerability. Brimonidine-Purite 0.1% is as effective in reducing IOP as the original Brimonidine 0.2% solution preserved with benzalkonium chloride. Recent results from preclinical and clinical studies suggest that Brimonidine may protect retinal ganglion cells and their projections from damage and death independently of its effects on IOP. The potential for neuroprotection with Brimonidine is an added benefit of its use in glaucoma and ocular hypertension.
-
Up-regulation of Brain-Derived Neurotrophic Factor Expression by Brimonidine in Rat Retinal Ganglion Cells
Archives of ophthalmology (Chicago Ill. : 1960), 2002Co-Authors: Hua Gao, Xiaoxi Qiao, Louis B. Cantor, Darrell WudunnAbstract:Objectives: Brimonidine tartrate ophth, an2-adrenergic agonist, is widely used as an antiglaucoma agent for lowering intraocular pressure. Recent studies suggest that Brimonidine may be neuroprotective for retinal ganglion cells (RGCs) following optic nerve crush injury. Brain-derived neurotrophic factor (BDNF), a potent neuroprotective factor present in the RGCs, promotes RGC survival in culture and following optic nerve injury. We tested the hypothesis that a possible mechanism of Brimonidine neuroprotection is through up-regulation of endogenous BDNF expression in the RGCs. Methods: A single dosage of Brimonidine tartrate ophth solution (0.85-34µM) was injected intravitreally into Sprague-Dawley rat eyes. The fellow eyes of each animal were injected with balanced salt solution (BSS) and used as control eyes. To determine BDNF messenger RNA expression, animal eyes were enucleated and processed for in situ hybridization, or retinas were isolated and processed for Northern blot analysis using rat BDNF radiolabeled riboprobes. Results: In the control eyes injected with saline, BDNF was present in a minority of the RGCs. Two days after Brimonidine injection, the number of BDNF-positive RGCs was increased from 55% to 166%, depending on Brimonidine concentrations, when compared with those in the controls. In addition, the BDNF signal intensities in individual RGCs were elevated 50% in Brimonidineinjected eyes compared with control eyes. Northern blot revealed a 28% increase of BDNF expression in the Brimonidine group compared with the controls (P .003). No significant difference was observed in BDNF receptor, trk B, expression between Brimonidine, or BSS control groups. Conclusions: A single dose of a low concentration of intravitreal Brimonidine is sufficient to significantly increase endogenous BDNF expression in RGCs. These results suggest that Brimonidine neuroprotection may be mediated through up-regulation of BDNF in the RGCs. The BDNF should be further investigated regarding its role in the neuroprotective effects reported with Brimonidine. Clinical Relevance: Brimonidine may be (potentially) used clinically as a neuroprotective agent in optic neuropathy, including glaucoma, and ischemic and traumatic optic neuropathy.
-
the evolving pharmacotherapeutic profile of Brimonidine an alpha 2 adrenergic agonist after four years of continuous use
Expert Opinion on Pharmacotherapy, 2000Co-Authors: Louis B. CantorAbstract:Since its introduction in 1996, use of Brimonidine tartrate 0.2% ophthalmic solution (Alphagan, Allergan), a highly selective alpha 2-adrenergic agonist, has become increasingly popular for the initial and long-term management of ocular hypertension and glaucoma. Recently, ongoing clinical comparison trials of up to three years in length have reported sustained intraocular pressure (IOP) lowering efficacy with Brimonidine 0.2% b.i.d., which was comparable with timolol 0.5% (Timoptic; Merck & Co.), accompanied by a favourable tolerability and safety profile. Also, many post-market studies have demonstrated the utility of Brimonidine 0.2% b.i.d. as mono- and adjunctive therapy. Furthermore, major inroads have been made in the study of other possible pharmacotherapeutic benefits of Brimonidine treatment, namely the potential for neuroprotection. This review will present a brief developmental history and examine key pharmacotherapeutic characteristics of Brimonidine, including its receptor selectivity, IOP-lowering mechanism of action and potential neuroprotective activities. Moreover, the literature on Brimonidine's efficacy and safety profiles in the treatment of ocular hypertension and glaucoma will be perused, and new four-year data from an ongoing double-masked clinical study comparing Brimonidine tartrate 0.2% with timolol 0.5%, b.i.d. will be introduced. Brimonidine 0.2% b.i.d. provided sustained IOP-lowering efficacy comparable to timolol 0.5% b.i.d., with no significant differences at trough or peak during year four of continuous use. Visual fields were well preserved in both treatment groups with 93% of Brimonidine patients and 91% of timolol patients showing no change or improvement. Brimonidine continued to appear safe and well-tolerated, with no clinically significant effects on mean heart rate or blood pressure, and no serious drug-related adverse events (AEs). Two out of 36 Brimonidine patients developed ocular allergy; both were resolved without sequelae. Overall post-market surveillance found no reports of unexpected or serious drug-related AEs. These long-term results, in conjunction with those reported in the literature, suggest that Brimonidine 0.2% b.i.d. is a highly appropriate first- and second-line therapy for long-term management of glaucoma and ocular hypertension. Potential neuroprotective effects of Brimonidine therapy, which might provide additional vision sparing benefit, although supported by compelling animal studies, await clinical verification.
Rhett M Schiffman - One of the best experts on this subject based on the ideXlab platform.
-
Control of intraocular pressure and fluctuation with fixed-combination Brimonidine-timolol versus Brimonidine or timolol monotherapy.
American journal of ophthalmology, 2011Co-Authors: George L. Spaeth, Paula Bernstein, Joseph Caprioli, Rhett M SchiffmanAbstract:Purpose To evaluate control of intraocular pressure (IOP) and IOP fluctuation in patients with ocular hypertension or glaucoma treated with fixed-combination Brimonidine–timolol compared with Brimonidine or timolol monotherapy. Design Post hoc analysis of data from 2 identical, 12-month, randomized, double-masked, multicenter trials. Methods Patients were treated bilaterally with fixed Brimonidine–timolol twice a day (n = 385), Brimonidine tartrate 0.2% 3 times a day (n = 382), or timolol 0.5% twice a day (n = 392). Diurnal IOP was measured at follow-up visits at weeks 2 and 6 and months 3, 6, 9, and 12. IOP fluctuation was defined as the standard deviation of IOP measurements. Results The percentage of patients with mean diurnal IOP P ≤ .017). At each hour (8 AM, 10 AM, 3 PM, and 5 PM), the percentage of patients with mean IOP P Conclusions Patients treated with fixed-combination Brimonidine–timolol were more likely than patients treated with either Brimonidine or timolol alone to achieve a combination of low mean IOP and low short-term (daily) or long-term (intervisit) IOP fluctuation.
-
twice daily 0 2 Brimonidine 0 5 timolol fixed combination therapy vs monotherapy with timolol or Brimonidine in patients with glaucoma or ocular hypertension a 12 month randomized trial
Archives of Ophthalmology, 2006Co-Authors: Mark B Sherwood, Harvey Dubiner, Rhett M Schiffman, Randy E Craven, Connie Chou, Amy L Batoosingh, Scott M WhitcupAbstract:Objective To evaluate the intraocular pressure (IOP)–lowering efficacy and safety of a fixed combination of 0.2% Brimonidine tartrate and 0.5% timolol maleate (fixed Brimonidine-timolol) compared with the component medications. Methods In 2 identical, 12-month, randomized, double-masked multicenter trials, patients with ocular hypertension or glaucoma were treated with fixed Brimonidine-timolol twice daily (n = 385), 0.2% Brimonidine tartrate 3 times daily (n = 382), or 0.5% timolol maleate twice daily (n = 392). Main Outcomes Measures Mean change from baseline IOP and incidence of adverse events. Results The mean decrease from baseline IOP during 12-month follow-up was 4.4 to 7.6 mm Hg with fixed Brimonidine-timolol, 2.7 to 5.5 mm Hg with Brimonidine, and 3.9 to 6.2 mm Hg with timolol. Mean IOP reductions were significantly greater with fixed Brimonidine-timolol compared with timolol at all measurements (P≤.002) and Brimonidine at 8AM, 10AM, and 3PM(P Conclusions Twice-daily fixed Brimonidine-timolol therapy provides sustained IOP lowering superior to monotherapy with either thrice-daily Brimonidine or twice-daily timolol and is better tolerated than Brimonidine but less well tolerated than timolol. Application to Clinical Practice Fixed Brimonidine-timolol is an effective and convenient IOP-lowering therapy.
-
Brimonidine and timolol fixed combination therapy versus monotherapy a 3 month randomized trial in patients with glaucoma or ocular hypertension
Journal of Ocular Pharmacology and Therapeutics, 2005Co-Authors: Randy E Craven, Connie Chou, Robert Williams, Thomas R Walters, Janet K Cheetham, Rhett M SchiffmanAbstract:Purpose: The aim of this study was to compare the safety and intraocular pressure (IOP)- lowering efficacy of a fixed combination of Brimonidine 0.2% and timolol 0.5% (fixed Brimonidine/ timolol) versus each drug used as monotherapy. Methods: Patients with glaucoma or ocular hypertension were randomized to receive fixed Brimonidine/timolol BID (n = 385), Brimonidine 0.2% TID (n = 382), or timolol 0.5% BID (n = 392) in a multicenter, double-masked study. The primary outcome measure was decrease from baseline IOP. Results: Over all follow-up measurements, the mean decrease from baseline IOP ranged from 4.9 to 7.6 mmHg with Brimonidine/timolol, from 3.1 to 5.5 mmHg with Brimonidine, and from 4.3 to 6.2 mmHg with timolol. Mean IOP reductions from baseline were significantly larger with fixed Brimonidine/timolol than with timolol at all follow-up measurements (P ≤ 0.026); the difference was greater than 1.5 mmHg at 10 AM (peak effect for each treatment). Mean IOP reductions from baseline were significantly lar...
Janet B Serle - One of the best experts on this subject based on the ideXlab platform.
-
a comparison of the safety and efficacy of twice daily Brimonidine 0 2 versus betaxolol 0 25 in subjects with elevated intraocular pressure
Survey of Ophthalmology, 1996Co-Authors: Janet B SerleAbstract:The safety and ocular hypotensive efficacy of twice-daily administration of Brimonidine 0.2% solution or betaxolol 0.25% suspension were compared in subjects with open-angle glaucoma or ocular hypertension. A total of 206 adult patients were enrolled in a prospective, 3-month, multicentered, randomized, double-masked, parallel-group study. Both drugs significantly (p < 0.001) reduced peak and trough intraocular pressure (IOP) at every scheduled follow-up visit over the 3-month study. At peak, the overall mean decrease from baseline IOP was greater (p = 0.004) in the Brimonidine-treated group (5.8 mm Hg) than in the betaxolol-treated group (3.8 mm Hg). At trough, the overall mean decrease from baseline (p < 0.001) was 3.9 mm Hg in the Brimonidine-treated group and 3.2 mm Hg in the betaxolol-treated group. The IOP-lowering effect of Brimonidine was sustained throughout the 3-month study period. Terminations from the study due to lack of efficacy included 2.9% (3/103) of patients in the Brimonidine group and 4.2% (4/96) of those in the betaxolol group. The overall incidence of adverse events was similar in both treatment groups, with the only significant (p = 0.027) between-group difference being that ocular blurring was reported more often by patients receiving betaxolol suspension than by those receiving Brimonidine treatment. Instillation of drug was reported to be comfortable (p = 0.036) by more Brimonidine-treated patients than betaxolol-treated patients. Overall, Brimonidine 0.2% solution was well-tolerated, safe and clinically and statistically more effective than betaxolol 0.25% suspension in lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
-
A comparison of the safety and efficacy of twice daily Brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III.
Survey of ophthalmology, 1996Co-Authors: Janet B SerleAbstract:The safety and ocular hypotensive efficacy of twice-daily administration of Brimonidine 0.2% solution or betaxolol 0.25% suspension were compared in subjects with open-angle glaucoma or ocular hypertension. A total of 206 adult patients were enrolled in a prospective, 3-month, multicentered, randomized, double-masked, parallel-group study. Both drugs significantly (p < 0.001) reduced peak and trough intraocular pressure (IOP) at every scheduled follow-up visit over the 3-month study. At peak, the overall mean decrease from baseline IOP was greater (p = 0.004) in the Brimonidine-treated group (5.8 mm Hg) than in the betaxolol-treated group (3.8 mm Hg). At trough, the overall mean decrease from baseline (p < 0.001) was 3.9 mm Hg in the Brimonidine-treated group and 3.2 mm Hg in the betaxolol-treated group. The IOP-lowering effect of Brimonidine was sustained throughout the 3-month study period. Terminations from the study due to lack of efficacy included 2.9% (3/103) of patients in the Brimonidine group and 4.2% (4/96) of those in the betaxolol group. The overall incidence of adverse events was similar in both treatment groups, with the only significant (p = 0.027) between-group difference being that ocular blurring was reported more often by patients receiving betaxolol suspension than by those receiving Brimonidine treatment. Instillation of drug was reported to be comfortable (p = 0.036) by more Brimonidine-treated patients than betaxolol-treated patients. Overall, Brimonidine 0.2% solution was well-tolerated, safe and clinically and statistically more effective than betaxolol 0.25% suspension in lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.